Update on pharmacological management of female sexual dysfunctions

Althof, 2005, Psychological and interpersonal dimensions of sexual function and dysfunction, J Sex Med, 2, 793, 10.1111/j.1743-6109.2005.00145.x Caruso, 2004, Placebo-controlled study on efficacy and safety of daily apomorphine SL intake in premenopausal women affected by hypoactive sexual desire disorder and sexual arousal disorder, Urologie, 63, 955, 10.1016/j.urology.2003.12.018 Caruso, 2006, Sildenafil improves sexual functioning in premenopausal women with type 1 diabetes who are affected by sexual arousal disorder: a double-blind, crossover, placebo-controlled pilot study, Fertil Steril, 85, 1496, 10.1016/j.fertnstert.2005.10.043 Caruso, 2012, Tadalafil 5mg par jour pour le traitement du diabète de type 1 chez les femmes préménopausées souffrant de troubles de l’excitation sexuelle, J Sex Med, 9, 2057, 10.1111/j.1743-6109.2012.02777.x Caruso, 2016, Quality of life and sexual function of naturally postmenopausal women on an ultralow-concentration estriol vaginal gel, Menopause, 23, 47, 10.1097/GME.0000000000000485 Caruso, 2018, Oxytocin plasma levels in orgasmic and anorgasmic women, Gynecol Endocrinol, 34, 69, 10.1080/09513590.2017.1336219 Constantine, 2015, Female sexual function improved with ospemifene in postmenopausal women with vulvar andvaginal atrophy: results of a randomized, placebo-controlled trial, Climacterique, 18, 226, 10.3109/13697137.2014.954996 D’Amati, 2002, Type 5 phosphodiesterase expression in the human vagina, Urology, 60, 191, 10.1016/S0090-4295(02)01663-1 Frick, 2004, Behavioral training interfères with the ability of gonadal hormones to increase CA1 spine synapse density in ovariectomized female rats, Eur J Neurosci, 19, 3026, 10.1111/j.0953-816X.2004.03427.x Gelman, 2017, Flibanserin for hypoactive sexual desire disorder: place in therapy, Ther Adv Chronic Dis, 8, 16, 10.1177/2040622316679933 Hinshelwood, 1997, Regulation of aromatase expression in the ovary and placenta: a comparison between two species, J Steroid Biochem Mol Biol, 61, 399, 10.1016/S0960-0760(97)80039-8 Jaspers, 2016, Efficacy and safety of flibanserin for the treatment of hypoactive sexual desire disorder in women. A systematic review and meta-analysis. Jaspers, JAMA Intern Med, 176, 453, 10.1001/jamainternmed.2015.8565 Kingsberg, 2015, The female sexual response: current models, neurobiological underpinnings and agents currently approved or under investigation for the treatment of hypoactive sexual desire disorder, CNS Drugs, 29, 915, 10.1007/s40263-015-0288-1 Muin, 2017, Men's sexual response to female partner's intranasal oxytocin administration for hypoactive sexual desire disorder: an open prospective cohort study, Fertil Steril, 107, 781, 10.1016/j.fertnstert.2016.12.003 Nappi, 2015, To be or not to be in sexual desire: the androgen dilemma, Climacteric, 18, 672, 10.3109/13697137.2015.1064268 Portman, 2017, Flibanserin in postmenopausal women with hypoactive sexual desire disorder: results of the PLUMERIA study, J Sex Med, 14, 834, 10.1016/j.jsxm.2017.03.258 Shozu, 1997, Estrogen biosynthesis in THP1 cells is regulated by promoter switching of the aromatase (CYP19) gene, Endocrinology, 138, 5125, 10.1210/endo.138.12.5562 Snabes, 2011 Yatawara, 2016, The effect of oxytocin nasal spray on social interaction deficits observed in young children with autism: a randomized clinical crossover trial, Mol Psychiatr, 21, 1225, 10.1038/mp.2015.162